How Valneva are changing the approach to vaccine clinical trials

You’ve invested millions of dollars, spent over a decade conducting trials and it’s only when you reach the final phase that you realize your product doesn’t even work. That can be the unfortunate reality for vaccine development. Few understand this better than Thomas Lingelbach, CEO of Valneva, a company focused on the development of innovative vaccines in areas of unmet medical need. With over twenty years of experience in the industry, having worked for Chiron, Novartis and Intercell, Thomas has overseen numerous vaccines go from bench to market.